Malignant mixed mullerian tumour of the ovary: Prognostic factor and response of adjuvant platinum‐based chemotherapy

Abstract

Malignant mixed mullerian tumour of the ovary is a rare and aggressive gynaecological tumour. The current study indicates that patient age was a significant prognostic factor for survival and surgical cytoreduction combined with platinum-based chemotherapy is the most effective management regimen identified to date to treat MMMT of the ovary.

Primary Treatment and Prognostic Factors of Carcinosarcoma of the Ovary, Fallopian Tube, and Peritoneum: A Taiwanese Gynecologic Oncology Group Study

“…10 However, we found that age was not associated with a poorer prognosis by the log-rank test (Table S1, Supplemental Digital Content 1, http://links.lww.com/IGC/A198), which is consistent with the findings reported by Rutledge et al, 11 who also found that age did not affect survival. It is reasonable to assume that early-stage disease may lead to a better prognosis; however, to the best of our knowledge, no studies to date have been able to demonstrate that stage is a prognostic factor using multivariate analysis.…”

“Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities”

“…Other clinical prognostic factors associated with poor outcome have been described in the literature, including older age and suboptimal surgical resection [4,21]. Optimal cytoreduction is associated with a survival benefit in women with advanced stage epithelial ovarian cancer [22], however, the reported benefit in patients with OCS is more variable ( Table 2).…”

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

“…Women >65 years of age have been reported as showing a significantly lower survival rate than younger women, although optimal debulking and the presence of a sarcomatous component were not significant prognostic factors for survival [27]. Cox multivariate analysis, including age, tumor stage, amount of residual disease, histology and type of adjuvant therapy, showed that tumor stage and adjuvant platinum-based chemotherapy in combination with paclitaxel or ifosfamide were predictors of a positive outcome [18].…”